Cargando…

Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers

BACKGROUND AND OBJECTIVES: IL27 and IL35 are regulatory T cells (T-regs) related cytokines; they were accused in eukemogenesis of acute myeloid leukemia (AML). This study aimed to assess the expression of these cytokines in de novo AML and investigate their role as biomarkers. SUBJECTS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Heba A, Maklad, Ahmed M, Khaled, Safaa AA, Elyamany, Ashraf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783395/
https://www.ncbi.nlm.nih.gov/pubmed/31686937
http://dx.doi.org/10.2147/JBM.S221301
_version_ 1783457540913233920
author Ahmed, Heba A
Maklad, Ahmed M
Khaled, Safaa AA
Elyamany, Ashraf
author_facet Ahmed, Heba A
Maklad, Ahmed M
Khaled, Safaa AA
Elyamany, Ashraf
author_sort Ahmed, Heba A
collection PubMed
description BACKGROUND AND OBJECTIVES: IL27 and IL35 are regulatory T cells (T-regs) related cytokines; they were accused in eukemogenesis of acute myeloid leukemia (AML). This study aimed to assess the expression of these cytokines in de novo AML and investigate their role as biomarkers. SUBJECTS AND METHODS: Seventy newly diagnosed patients with primary AML and 30 matched healthy volunteers were recruited. AML diagnosis was confirmed with flowcytometric and immunophenotypic analyses, while ELISA was used to assess serum levels of IL27 and IL35 in patients and controls. Receiver operating characteristic curve analysis was used to estimate IL27 and IL35 optimum cutoff values for predicting AML. RESULTS: Serum levels of both cytokines were significantly higher in AML patients than controls (P<0.001), with no effect of gender or French-American-British subtypes. Significant correlations of IL27 and IL35 with poor prognostic factors and with each other were detected in patients only. IL27 optimum cutoff for predicting AML was >43, AUC (0.926) with a sensitivity 74% and specificity 96.6% (P<0.001), while for IL35>27.8, AUC (0.972) with 88% and 98% sensitivity and specificity, respectively (P<0.001). CONCLUSION: Conclusively, this study proved that IL27and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique we recommend the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML; however, further longitudinal research is needed to prove their exact prognostic value.
format Online
Article
Text
id pubmed-6783395
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67833952019-11-04 Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers Ahmed, Heba A Maklad, Ahmed M Khaled, Safaa AA Elyamany, Ashraf J Blood Med Original Research BACKGROUND AND OBJECTIVES: IL27 and IL35 are regulatory T cells (T-regs) related cytokines; they were accused in eukemogenesis of acute myeloid leukemia (AML). This study aimed to assess the expression of these cytokines in de novo AML and investigate their role as biomarkers. SUBJECTS AND METHODS: Seventy newly diagnosed patients with primary AML and 30 matched healthy volunteers were recruited. AML diagnosis was confirmed with flowcytometric and immunophenotypic analyses, while ELISA was used to assess serum levels of IL27 and IL35 in patients and controls. Receiver operating characteristic curve analysis was used to estimate IL27 and IL35 optimum cutoff values for predicting AML. RESULTS: Serum levels of both cytokines were significantly higher in AML patients than controls (P<0.001), with no effect of gender or French-American-British subtypes. Significant correlations of IL27 and IL35 with poor prognostic factors and with each other were detected in patients only. IL27 optimum cutoff for predicting AML was >43, AUC (0.926) with a sensitivity 74% and specificity 96.6% (P<0.001), while for IL35>27.8, AUC (0.972) with 88% and 98% sensitivity and specificity, respectively (P<0.001). CONCLUSION: Conclusively, this study proved that IL27and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique we recommend the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML; however, further longitudinal research is needed to prove their exact prognostic value. Dove 2019-10-01 /pmc/articles/PMC6783395/ /pubmed/31686937 http://dx.doi.org/10.2147/JBM.S221301 Text en © 2019 Ahmed et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ahmed, Heba A
Maklad, Ahmed M
Khaled, Safaa AA
Elyamany, Ashraf
Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title_full Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title_fullStr Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title_full_unstemmed Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title_short Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
title_sort interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783395/
https://www.ncbi.nlm.nih.gov/pubmed/31686937
http://dx.doi.org/10.2147/JBM.S221301
work_keys_str_mv AT ahmedhebaa interleukin27andinterleukin35indenovoacutemyeloidleukemiaexpressionandsignificanceasbiologicalmarkers
AT makladahmedm interleukin27andinterleukin35indenovoacutemyeloidleukemiaexpressionandsignificanceasbiologicalmarkers
AT khaledsafaaaa interleukin27andinterleukin35indenovoacutemyeloidleukemiaexpressionandsignificanceasbiologicalmarkers
AT elyamanyashraf interleukin27andinterleukin35indenovoacutemyeloidleukemiaexpressionandsignificanceasbiologicalmarkers